Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

214
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

263
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
263
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

196
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
196
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

257
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
257

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Breaking the seizure cycle: Belgian expert consensus on the diagnostics and treatment of acute convulsive seizures in children.

Acta neurologica Belgica·2026
Same author

Management of imported malaria in the emergency department: Adequacy compared to guidelines, and impact of the SARS-CoV-2 pandemic.

Infectious diseases now·2023
Same author

[How I explore... macrocephaly].

Revue medicale de Liege·2022
Same author

[How I explore… autism spectrum disorder in a child].

Revue medicale de Liege·2021
Same author

[Heredity and cancer].

Revue medicale de Liege·2021
Same author

[How I explore… a disorder of intellectual development in a child].

Revue medicale de Liege·2020

Related Experiment Video

Updated: Jan 21, 2026

Guidelines for Elective Pediatric Fiberoptic Intubation
11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

18.4K

[Periventricular nodular heterotopia : a pediatric case].

I Ebetiuc1, S Bulk2, P Leroy1

  • 1Service de Pédiatrie, CHU Liège, Belgique.

Revue Medicale De Liege
|August 3, 2019
PubMed
Summary
This summary is machine-generated.

Periventricular nodular heterotopia (PVNH) is a rare brain malformation caused by FLNA gene mutations, predominantly affecting females. This condition leads to seizures, developmental delays, and potential cardiovascular issues, requiring multidisciplinary care.

Keywords:
EpilepsyMental retardationPeriventricular nodular heterotopia

More Related Videos

Mouse Models of Periventricular Leukomalacia
06:24

Mouse Models of Periventricular Leukomalacia

Published on: May 18, 2010

30.4K
Evaluating the Effects of Different Polishing Methods on Color Stability of Dental Restorations in Pediatric Dentistry
03:37

Evaluating the Effects of Different Polishing Methods on Color Stability of Dental Restorations in Pediatric Dentistry

Published on: June 6, 2025

398

Related Experiment Videos

Last Updated: Jan 21, 2026

Guidelines for Elective Pediatric Fiberoptic Intubation
11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

18.4K
Mouse Models of Periventricular Leukomalacia
06:24

Mouse Models of Periventricular Leukomalacia

Published on: May 18, 2010

30.4K
Evaluating the Effects of Different Polishing Methods on Color Stability of Dental Restorations in Pediatric Dentistry
03:37

Evaluating the Effects of Different Polishing Methods on Color Stability of Dental Restorations in Pediatric Dentistry

Published on: June 6, 2025

398

Area of Science:

  • Neuroscience
  • Genetics
  • Developmental Biology

Background:

  • Periventricular nodular heterotopia (PVNH) is a congenital cerebral cortex malformation.
  • It arises from deletions or duplications in the FLNA gene on the X chromosome, encoding a cytoskeleton protein.
  • PVNH belongs to the heterogeneous group of philaminopathies with dominant inheritance.

Observation:

  • The condition exhibits a female predominance, with males often experiencing early lethality.
  • Clinical manifestations include seizure disorders (mild to intractable), mental retardation, hypotonia, and cardiovascular abnormalities.
  • Associated complications involve vasculopathy and coagulopathy, potentially leading to stroke.

Findings:

  • The FLNA gene mutation is the underlying cause of PVNH.
  • The X-linked dominant inheritance pattern explains the observed sex bias.
  • A spectrum of neurological and systemic abnormalities characterizes the clinical presentation.

Implications:

  • Multidisciplinary team surveillance is crucial for managing patients with PVNH.
  • Genetic counseling is essential for affected families.
  • Understanding FLNA gene function is key to developing targeted therapies for PVNH and related disorders.